Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4006
Name bladder urothelial carcinoma
Definition A bladder carcinoma that has_material_basis_in transitional cells located_in the lining of the bladder.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder urothelial carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KDR act mut Sunitinib bladder urothelial carcinoma predicted - sensitive detail...
FGFR3 - TACC3 PRN1371 bladder urothelial carcinoma sensitive detail...
FGFR3 mutant Infigratinib bladder urothelial carcinoma sensitive detail...
KDM6A loss GSK343 bladder urothelial carcinoma sensitive detail...
FGFR3 mutant Dovitinib bladder urothelial carcinoma sensitive detail...
FGFR3 S249C Dovitinib bladder urothelial carcinoma sensitive detail...
KDM6A loss GSK503 bladder urothelial carcinoma sensitive detail...
KDM6A loss GSK126 bladder urothelial carcinoma sensitive detail...
KDM6A loss Tazemetostat bladder urothelial carcinoma sensitive detail...
Unknown unknown Pembrolizumab bladder urothelial carcinoma not applicable detail...
FGFR2 mutant Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 mutant Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 R248C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 S249C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 Y373C Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 - TACC3 Erdafitinib bladder urothelial carcinoma sensitive detail...
FGFR3 G370C Erdafitinib bladder urothelial carcinoma sensitive detail...
Unknown unknown VAX014 bladder urothelial carcinoma not applicable detail...
FGFR3 A391E AZD4547 bladder urothelial carcinoma predicted - sensitive detail...
ARID1A mutant Nivolumab bladder urothelial carcinoma predicted - sensitive detail...
ARID1A mutant Atezolizumab bladder urothelial carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting
NCT01108055 Phase II Paclitaxel + Pazopanib Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Completed
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01215136 Phase II Everolimus Paclitaxel First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Terminated
NCT01326871 Phase Ib/II ALT-801 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status
NCT01438112 Phase II Valrubicin Mitomycin C CG0070 interferon gamma Gemcitabine Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) Terminated
NCT01625260 Phase Ib/II ALT-801 ALT-801 + Gemcitabine A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Unknown status
NCT01780545 Phase II Apatorsen Docetaxel Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Completed
NCT01916109 Phase II Carboplatin + Gemcitabine + Panitumumab Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Terminated
NCT02009332 Phase Ib/II Sirolimus Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer Completed
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Active, not recruiting
NCT02108652 Phase II Atezolizumab A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Active, not recruiting
NCT02122172 Phase II Afatinib Afatinib in Advanced Refractory Urothelial Cancer Recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Active, not recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02197897 Phase II Tamoxifen Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors Unknown status
NCT02236195 Phase II Mocetinostat Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Completed
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed
NCT02256436 Phase III Pembrolizumab A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Active, not recruiting
NCT02300610 Phase I Cisplatin + Gemcitabine Enzalutamide Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Completed
NCT02302807 Phase III Paclitaxel Vinorelbine Atezolizumab Docetaxel A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02324582 Phase I Pembrolizumab MK-3475/BCG in High Risk Superficial Bladder Cancer Active, not recruiting
NCT02334527 Phase II Palbociclib Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy Terminated
NCT02335424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) Active, not recruiting
NCT02351739 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer Completed
NCT02365766 Phase Ib/II Cisplatin Pembrolizumab Gemcitabine Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer Active, not recruiting
NCT02365818 Phase II CG0070 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure Completed
NCT02387996 Phase II Nivolumab A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer Active, not recruiting
NCT02401542 Phase Ib/II Docetaxel + Vofatamab Vofatamab Docetaxel Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21) Terminated
NCT02426125 Phase III Ramucirumab Docetaxel A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Active, not recruiting
NCT02449239 Phase III Oportuzumab monatox Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Active, not recruiting
NCT02450331 Phase III Atezolizumab A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) Active, not recruiting
NCT02451423 Phase II Atezolizumab Study of MPDL3280A in Bladder Cancer Recruiting
NCT02459119 Phase II Regorafenib Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Completed
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated
NCT02496208 Phase I Ipilimumab Cabozantinib + Nivolumab Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Recruiting
NCT02500121 Phase II Pembrolizumab Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer Active, not recruiting
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Active, not recruiting
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated
NCT02567409 Phase II Cisplatin + Gemcitabine Berzosertib + Cisplatin + Gemcitabine Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer Active, not recruiting
NCT02581982 Phase II Pembrolizumab Paclitaxel Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Active, not recruiting
NCT02589717 FDA approved Atezolizumab An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy Approved for marketing
NCT02608125 Phase I PRN1371 A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma Active, not recruiting
NCT02612194 Phase II Crizotinib LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Active, not recruiting
NCT02619253 Phase Ib/II Pembrolizumab + Vorinostat Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Active, not recruiting
NCT02621151 Phase II Pembrolizumab Gemcitabine Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Recruiting
NCT02625961 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Recruiting
NCT02632409 Phase III Nivolumab A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma Active, not recruiting
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02657486 Phase 0 Infigratinib BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder Active, not recruiting
NCT02690558 Phase II Cisplatin + Gemcitabine + Pembrolizumab Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy Active, not recruiting
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Active, not recruiting
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Recruiting
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed
NCT02792192 Phase Ib/II Atezolizumab + BCG solution Atezolizumab Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants Active, not recruiting
NCT02807636 Phase III Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy Active, not recruiting
NCT02812420 Phase I Durvalumab + Tremelimumab Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy Active, not recruiting
NCT02844816 Phase II Atezolizumab Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer Active, not recruiting
NCT02845323 Phase II Urelumab Nivolumab + Urelumab Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder Recruiting
NCT02853305 Phase III Pembrolizumab Carboplatin + Cisplatin + Gemcitabine Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Active, not recruiting
NCT02872714 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Recruiting
NCT02891161 Phase Ib/II Durvalumab Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Active, not recruiting
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed
NCT02901548 Phase II Durvalumab Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder Recruiting
NCT02925533 Phase I Pembrolizumab + Vofatamab Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Terminated
NCT02989064 Phase I MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers Active, not recruiting
NCT02989584 Phase Ib/II Atezolizumab + Cisplatin + Gemcitabine A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer Active, not recruiting
NCT03022825 Phase II ALT-803 + BCG solution QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer Recruiting
NCT03093922 Phase II Atezolizumab + Cisplatin + Gemcitabine A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Recruiting
NCT03106610 Phase I Nivolumab Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy Terminated
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03150836 Phase II Durvalumab Durvalumab + Tremelimumab Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer Withdrawn
NCT03170960 Phase Ib/II Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03171493 Phase I MV-NIS Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy Recruiting
NCT03237780 Phase II Atezolizumab Atezolizumab + Eribulin Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Suspended
NCT03258593 Phase I Durvalumab + Oportuzumab monatox Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Recruiting
NCT03272217 Phase II Atezolizumab + Bevacizumab Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Recruiting
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Active, not recruiting
NCT03359239 Phase I Atezolizumab + PGV 001 Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Recruiting
NCT03361865 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Active, not recruiting
NCT03374488 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Active, not recruiting
NCT03375307 Phase II Olaparib Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects Recruiting
NCT03397394 Phase II Rucaparib Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) Completed
NCT03410693 Phase II Rogaratinib Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) Active, not recruiting
NCT03421652 Phase II Nivolumab Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy Recruiting
NCT03451331 Phase II Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Recruiting
NCT03459846 Phase II Durvalumab + Olaparib Durvalumab A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) Active, not recruiting
NCT03473730 Phase I Daratumumab Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer Recruiting
NCT03473756 Phase Ib/II Atezolizumab Atezolizumab + Rogaratinib Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) Recruiting
NCT03498196 Phase Ib/II Avelumab A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Terminated
NCT03502681 Phase I Avelumab + Eribulin A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients Terminated
NCT03502785 Phase Ib/II Atezolizumab + INO-5401 + INO-9012 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Active, not recruiting
NCT03513952 Phase II Atezolizumab + CYT107 Atezolizumab Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Recruiting
NCT03517956 Phase I Copanlisib + Rogaratinib Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) Active, not recruiting
NCT03518320 Phase I Gemcitabine + Nivolumab Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Terminated
NCT03519256 Phase II BMS-986205 + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + BMS-986205 + Nivolumab A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) Recruiting
NCT03520231 Phase II Carboplatin + Cisplatin + Denosumab + Gemcitabine Carboplatin + Cisplatin + Gemcitabine Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Recruiting
NCT03520491 Phase II Ipilimumab + Nivolumab Nivolumab A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy Recruiting
NCT03532451 Phase I Lirilumab + Nivolumab Nivolumab Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807) Active, not recruiting
NCT03557918 Phase II Tremelimumab Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Recruiting
NCT03575013 Phase I Avelumab + Docetaxel A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer Recruiting
NCT03601455 Phase II Durvalumab + Tremelimumab Durvalumab Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer Recruiting
NCT03617913 Phase II Avelumab + Cisplatin + Fluorouracil + Mitomycin C Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Active, not recruiting
NCT03620435 Phase II Atezolizumab Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer Recruiting
NCT03628716 Phase II Atezolizumab + CV301 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Active, not recruiting
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT03682068 Phase III Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) Recruiting
NCT03711032 Phase III BCG solution + Pembrolizumab BCG solution Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Recruiting
NCT03732677 Phase III Cisplatin + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA) Recruiting
NCT03737123 Phase II Atezolizumab + Carboplatin + Gemcitabine Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Recruiting
NCT03768570 Phase II Durvalumab Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer Recruiting
NCT03773666 Phase I Durvalumab + Oleclumab Durvalumab A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Recruiting
NCT03775265 Phase III Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Recruiting
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03854721 Phase I VAX014 A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer Recruiting
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting
NCT03869190 Phase Ib/II Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) Recruiting
NCT03898180 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Recruiting
NCT03912818 Phase II Cisplatin + Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Carboplatin + Durvalumab + Gemcitabine Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Recruiting
NCT03914794 Phase II Pemigatinib A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Recruiting
NCT03915405 Phase I Avelumab + KHK2455 KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Recruiting
NCT03934814 Phase I TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Recruiting
NCT03935347 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Withdrawn
NCT03978624 Phase II Pembrolizumab Entinostat + Pembrolizumab Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Recruiting
NCT03980041 Phase II Nivolumab IPI-549 + Nivolumab Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Recruiting
NCT04004442 Phase II AVB-S6-500 + Avelumab Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN) Recruiting
NCT04040725 Phase II Rogaratinib Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Withdrawn
NCT04045613 Phase Ib/II Derazantinib Atezolizumab + Derazantinib Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02) Recruiting
NCT04073160 Phase I Durvalumab Durvalumab + Tremelimumab TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) Withdrawn
NCT04109092 Phase I E7766 A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 Recruiting
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting
NCT04164082 Phase II Gemcitabine + Pembrolizumab Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Suspended
NCT04165317 Phase III BCG solution + PF-06801591 BCG solution Study of PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer. (B8011006) Recruiting
NCT04289779 Phase II Atezolizumab + Cabozantinib Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE) (ABATE) Recruiting
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Recruiting
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting
NCT04430036 Phase II Balstilimab + Cisplatin + Gemcitabine + Zalifrelimab AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Not yet recruiting
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting